Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility of Total Neoadjuvant Therapy in Resectable Biliary Adenocarcinoma

NCT04480190 is registered in ClinicalTrials.gov with Jordan Kharofa as lead sponsor.

NCT NCT04480190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04480190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility of Total Neoadjuvant Therapy in Resectable Biliary Adenocarcinoma
Lead sponsor
Jordan Kharofa
Phase
Phase 1
Overall status
Withdrawn
Start date
February 4, 2021
Completion date
April 4, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary cancer, cholangiocarcinoma